StockData
Attovia Therapeutics, Inc. logo

Attovia Therapeutics, Inc. (ATTO) company profile

ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$14.86+0.13 (+0.92%)

Close on Nov 17, 2026Market cap $678.38MP/E –Yield –

About Attovia Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Attovia Therapeutics, Inc. is listed on Nasdaq under the ticker ATTO, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.

Company profile

Company

Legal name
Attovia Therapeutics, Inc.
Headquarters
San Carlos, CA
Address
1091 Industrial Road 94070
Phone
(510) 399-5001
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
ATTO
Exchange
Nasdaq
IPO date
Aug 5, 2026
Shares outstanding
46M, Aug 31, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
2058707
CUSIP
04987L102
ISIN
US04987L1026
FIGI
BBG01H3TV5J8
Share class FIGI
BBG01H3TV5L5
EIN
92-1510574

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Tao FuPresident and CEO, Director333,268
Attovia Therapeutics, Inc.President and CEO, Director449,371
Steven ChanChief Financial Officer–
Petter VeibyChief Scientific Officer104,951
Hubert ChenChief Medical Officer2,960
Zaneta OdrowazChief Business Officer103,269
Colin WalshDirector2,520,632
Angie YouDirector52,852
Mitchell GoldDirector–
John W. SmitherDirector–
Aaron RoystonDirector–
James N. TopperDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 5, 2026
Offer price
$17.00
Securities offered
17,000,000
Gross proceeds
$289.00M
Exchange
Nasdaq
Lock-up ends (est.)
Feb 1, 2027

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?